Novacyt S.A.: Coronavirus test update
16 Março 2020 - 4:00AM
Business Wire
Initial orders from Public Health England
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international
specialist in clinical diagnostics, is pleased to provide an update
regarding the novel coronavirus (COVID-19) test developed by
Primerdesign, its molecular diagnostics division.
Following the completion of Public Health England’s (PHE) formal
evaluation of Primerdesign’s COVID-19 test, as announced on 12
March 2020, the government agency has commenced ordering the test.
Orders are initially for eight hospitals to provide stocks in those
locations for four weeks of planned testing. The total value of the
initial purchase is approximately £1.0 million (€1.1 million),
which is the single largest order the Company has received to date
for its COVID-19 test.
As of 13 March 2020, Primerdesign has sold and received orders
for over £3.7 million (€4.3 million) of its CE-Mark and research
use only (RUO) COVID-19 tests, which includes the order received
from PHE. This represents approximately eight months of sales for
the division under normal circumstances. This is additional revenue
to the core Novacyt business.
Graham Mullis, Chief Executive Officer of Novacyt,
commented: “We welcome Public Health England’s decision to use
our COVID-19 test in the UK and I am delighted to see that Novacyt
will now be supporting one of its home markets during these
challenging times. The number of countries Novacyt is now supplying
with its COVID-19 test has reached over 60 and we expect this will
continue to increase.
“The team at Novacyt and its key suppliers are working extremely
hard to support clinicians around the world in the fight against
this pandemic and, as a Chief Executive Officer, I am immensely
proud of everyone’s commitment.”
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
About COVID-19
Researchers at the Chinese Centre for Disease Control and
Prevention and their collaborators have sequenced the 2019 novel
coronavirus (COVID-19) pathogen from patient samples and have found
it to be genetically distinct from the severe acute respiratory
syndrome (SARS) virus that caused an epidemic in 2002 and 2003, as
well as from the Middle East respiratory syndrome (MERS) virus that
was detected in 2012.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200316005189/en/
Novacyt SA Graham Mullis, Chief Executive Officer Anthony
Dyer, Chief Financial Officer +44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470
0470
FTI Consulting (International) Victoria Foster Mitchell /
Mary Whittow +44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France) Arnaud de Cheffontaines +33
(0)147 03 69 47 arnaud.decheffontaines@fticonsulting.com
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024